Westfield Capital Management CO LP Clovis Oncology, Inc. Transaction History

Westfield Capital Management CO LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$12.81 - $25.67 $10.3 Million - $20.7 Million	-806,465 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$17.66 - $30.28 $14.2 Million - $24.4 Million	806,465 New	806,465 $20 Million
Q4 2018 Feb 08, 2019	SELL	$11.63 - $32.67 $7.6 Million - $21.4 Million	-653,658 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $4.36 Million - $7.34 Million	-148,410 Reduced 18.5%	653,658 $19.2 Million
Q2 2018 Aug 13, 2018	BUY	$42.06 - $62.4 $10.6 Million - $15.7 Million	251,753 Added 45.75%	802,068 $36.5 Million
Q1 2018 May 14, 2018	BUY	$50.12 - $67.72 $2.24 Million - $3.03 Million	44,760 Added 8.85%	550,315 $29.1 Million
Q4 2017 Feb 13, 2018	BUY	$57.69 - $84.58 $2.66 Million - $3.9 Million	46,085 Added 10.03%	505,555 $34.4 Million
Q3 2017 Nov 13, 2017	BUY	$67.17 - $84.81 $30.9 Million - $39 Million	459,470	459,470 $37.9 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Westfield Capital Management CO LP, based on Form 13F filings with the SEC.

Stay updated on Westfield Capital Management CO LP with notifications on news.